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Abstract. Today the amount of software content within medical devices has 
grown considerably and will continue to do so as the level of complexity of 
medical devices  continues to increase.  This is driven by the fact that 
software is introduced to produce sophisticated medical devices that would 
not be possible using only hardware. This therefore presents opportunities for 
software development SMEs to become medical device software 
development organisations. However, some obstacles need to be addressed 
and overcome in order to make the transition from being a generic software 
development organisation to becoming a medical device software 
development organisation. This paper describes these obstacles and how 
research that is currently being performed within the Regulated Software 
Research Group in Dundalk Institute of Technology may be used to assist 
with this transition. 
 
 
Introduction - Background to Medical Device Software 
Development 
  
Today software is an increasingly important component of medical devices, as 
it enables often complex functional changes to be implemented without 
necessitating changes to the hardware [1]. As a consequence of the 
increasing demands for greater functionality within medical devices, the 
complexity of medical device software development also continues to  
increase [2]. This has resulted in increased demand for appropriate 
traceability and risk management processes and tools.  
 
It is very important that highly effective software development practices are in 
place within medical device companies due to the safety-critical nature o 
medical device software. In order to sell their products medical device 
companies must comply with the regulatory requirements of the countries in 
which they wish to market their devices [3]. Governments have put in place 
regulatory bodies to tackle these issues whose role is to define regulatory 
systems for medical devices and to ensure that only safe medical devices are 
placed on the market [4].  
 
While regulatory bodies offer some guidance on what software activities must 
be performed, no specific method for performing these activities is provided or 
enforced [5]. In this context in the United States (US), the Food and Drug 
Administration (FDA) Center for Devices and Radiological Health (CDRH) has 
published guidance papers which include risk-based activities to be performed 
during software validation [6], pre-market submission [7] and when using off-
the-shelf software in a medical device [8].  Although the CDRH guidance 
documents provide information on which software activities should be 
performed, they do not enforce any specific method for performing these 
activities. This can result in medical device software companies failing to 
comply with the expected requirements. 
 
To help address this situation an important  decision was taken by the 
medical device industry to recognize ISO/IEC 12207:1995 [9] (a general 
software engineering lifecycle process standard) as suitable for general 
medical device software development.  Subsequently the Association for the 
Advancement of Medical Instrumentation (AAMI) software committee carefully 
reviewed ISO/IEC 12207:1995 and identified a number of shortcomings due 
to the fact that it was a generic standard. This resulted in the decision to 
create a new standard which was domain specific to medical device software 
development. The AAMI did not discard the work done with the ISO/IEC 
12207:1995 and used it as the foundation for their new standard “AAMI 
SW68, Medical device software – Software lifecycle processes” [10]. In 2006, 
a new standard IEC 62304 [11] was released that was based on the AAMI 
SW68 standard. 
 
The Council of the European Communities published in 1993  the  Directive 
93/42/EEC (1993) [12], the “Medical Device Directive” (MDD), on medical 
devices. The MDD is intended to ensure the safety of medical devices placed 
on the market in the European Union (EU), and has the backing of national 
legislation in member states.  Amendments to this directive occurred via 
Directives 2000/70/EC (2000) [13], 2001/104/EC (2001) [14], 2003/32/EC 
(2003) [15], and 2007/47/EC (2007) [16].   
 
Whenever we mention medical device guidelines within this paper we refer to 
the following medical device standards and guidelines: IEC 62304, FDA, the 
MDD, ISO 14971 [17], EN 60601-4 [18], TIR 32 [19], IEC TR 80002-1[20], IEC 
62366 [21],GAMP 5 [22], IEC/TR 61508 [23], ISO 13485[24] and IEC 60812 
[25].  
 
The remainder of this paper is structured in the following way.  Section 2 
considers the reasons why software Small and Medium sized Enterprises 
(SMEs) are interested in becoming medical device SMEs and the challenges 
they face.  In section 3 recent changes made by the EU and FDA regarding 
medical device software are discussed. Section 4 outlines the research 
currently being undertaken by the Regulated Software Research Group 
(RSRG) in Dundalk Institute of Technology which is of particular value to 
assist SMEs to develop medical device software.  Section 5 discusses what 
initial steps can be taken by SMEs when embarking on medical device 
software development. A conclusion is provided in section 6 and future work 
is outlined 
 
 
Why Software SMEs are Interested in Becoming Medical Device SMEs 
 
Software development SMEs are currently becoming medical device software 
development SMEs for two main reasons. The first of these is medical 
devices are becoming increasingly more complex and software facilitates 
increased functionality without the necessity to replace hardware. Therefore, 
due to growth in this area for this type of software there is an opportunity for 
software development SMEs to   become medical device software 
development SMEs. The second reason is that software development SMEs 
currently developing health related software applications may now be actually 
developing medical device software.  This is due to the most recent  revision 
of the of Medical Device Directive [16], which states that standalone software 
may now be defined as a medical device. 
 
The challenge both types of organizations face is that to become a medical 
device software SME requires that software be developed in a regulatory 
compliant manner. This is essential as in order for a medical device to be 
marketed it is first necessary to achieve regulatory approval for the device in 
the region where it will be sold. This therefore means that such organizations 
need to become aware of what developing regulatory compliant software 
means and how they will have to change their current software development 
processes in order to fulfill this requirement. The starting point for such 
organizations is to become aware of the relevant regulations. 
 
 
Changes Impacting Medical Device Software Development 
 
As medical devices are safety critical, they are subject to stringent regulations 
before they can be approved for use. Within the US medical devices must be 
approved by the FDA and likewise, medical devices for use within the EU 
must carry a CE conformance mark. This is awarded by notified bodies in 
each country. The most recent changes in the regulations, with regard to 
medical device software development, is the European MDD (2007/47/EC) 
[16] and the FDA Final Rule on Medical Device Data Systems [26] 
 
On March 21
st
 2010, the MDD (2007/47/EC) came into force in the EU. This 
directive amends the MDD (93/42/EEC) [12], the Active Implantable Medical 
Device directive (90/385/EEC) [27] and the Biocides directive (98/8/EC) [28]. 
The most significant amendment within the MDD (2007/47/EC) is the 
provision for standalone software to be used as an active medical device.  
The MDD (2007/47/EC) Annex IX Section 1.4 states: “stand-alone software is 
considered to be an active medical device”. It defines an active medical 
device as “any medical device operation which depends on a source of 
electrical energy or any source of power other than that generated by the 
human body or gravity”[16]. 
 
 Consequently, standalone medical device software is now subject to 
regulation, independent of the hardware on which it resides. As software can 
now be seen as the only component of a medical device, improved guidance 
is needed in the development of this type of software to achieve regulatory 
compliance. While the MDD provides medical device manufacturers with a list 
of harmonized standards which can be used during development to aid in 
achieving regulatory compliance. However, no harmonized standards exist 
that can provide full guidance in the development of standalone software as 
an active medical device.  The FDA does not provide software or standalone 
software specific regulations. They regulate medical devices and the elements 
that are included as part of that device, with software being regulated in this 
context. To help address this the FDA provide relevant guidance documents 
to assist with medical device software development [7], [6], [8]. 
 
On April 18th 2011, the FDA Final Rule reclassifying Medical Device Data 
systems (MDDS) as Class I medical devices became effective [26]. MDDS’s 
are off-the-shelf or custom software or hardware products used alone, or in 
combination, that display unaltered medical device data or transfer, store or 
convert medical device data for future use, in accordance with a pre-set 
specification. Prior to the release of this final rule, MDDS were classified as 
Class III devices or as an accessory to the parent device, requiring the 
greatest amount of scrutiny before approval could be awarded. 
 
 Whilst this ruling will make it simpler for companies developing MDDS 
software, it will also ring fence those which were previously beyond the net of 
regulatory requirements and make them subject to regulation.  In addition, as 
part of this final rule a caveat was added to exclude devices that are used to 
actively monitor patients from being included as a MDDS. These devices 
remain classified as accessories and must undergo the same amount of 
regulatory conformance as the parent device to which they are connected 
[29]. Also standalone software such as Electronic Health Records (EHR) and 
Computerized Physician Order Entry (CPOE) fall outside of the scope of 
being defined as MDDS. 
 
Research to Help SMEs Develop Medical Device Software  
 
The RSRG was established in Dundalk Institute of Technology  in February 
2008.   The research undertaken by the RSRG is focused on the development 
of an international Software Process Improvement (SPI) framework for the 
medical device industry. The objective of this framework is to provide a key 
enabler of best practice for the sector. 
 
The RSRG have undertaken a multi-faceted approach to establishing this 
framework including the examination of best practice from other safety-critical 
domains and determining how best practice SPI models can be successfully 
mapped onto regulatory frameworks.  This has taken place through close 
cooperation with the medical device industry, relevant international standards 
bodies and the software process improvement community.  A key element of 
this research is the use of empirical studies of industrial practice which has 
been utilized to inform theory.  To undertake this work the RSRG have 
adopted a range of quantitative and qualitative research methodologies 
including experiments, quantitative analysis of data sets, case studies, action 
research and grounded theory to provide a rich analysis of the domain. 
 
The main focus of the RSRG is to support the growth of the medical device 
software industry within Ireland. However, this does not mean that their 
research has been restricted to Ireland, in fact the RSRG collaborates closely 
with international medical device organizations and SPI researchers. In 
particular, the RSRG is working as part of an international working group to 
revise the International Standard for Software Medical Device Software 
Lifecycle Processes (IEC 62304) and also closely with the Spice User Group 
to develop Medi SPICE [30]. Whilst the main deliverable for the RSRG is Medi 
SPICE they have also developed a number of lightweight assessment 
methods to assist software SMEs to become medical device software SMEs. 
The following subsections describe Medi SPICE and the lightweight 
assessment methods Med-Trace, Med-Adept and Medi SPICE-Adept. 
 
 
Medi SPICE 
 
Medi SPICE [30], [5] is a process assessment and improvement model which 
is domain specific to medical device software development and incorporates 
regulatory compliance.  The results of a Medi SPICE assessment may be 
used to indicate the state of a medical device suppliers software practices in 
relation to the regulatory requirements of the industry, and identify areas for 
process improvement. The results of an assessment may also be used as a 
criterion for supplier selection.  
 
Medi SPICE is based upon ISO/IEC 15504-5 [31] and provides coverage of 
the medical device software regulations. Like ISO/IEC 15504-5 and 
Automotive SPICE [32] it contains both a Process Reference Model (PRM) 
and Process Assessment Model (PAM) containing processes that provide 
comprehensive coverage of the FDA and European Council directives, and 
associated standards (e.g. ISO 14971, ISO 13485, IEC TR 80002-1,  IEC 
62304) for the complete software development lifecycle. 
 
The overall objective of Medi SPICE is to provide a conformity assessment 
scheme to support first, second or third party assessment results that may be 
recognized by the regulatory bodies. The PRM and PAM of the Medi SPICE 
assessment model is derived from relevant ISO/IEC 15504-5 processes as 
they are all applicable to the development of safety-critical medical device 
software. As the IEC 62304 standard contains the medical device software 
lifecycle processes that have to be adhered to in order to achieve medical 
device regulatory compliance, a key objective is to provide coverage of all 
processes that are either included in or referenced from IEC 62304 and its 
associated standards. 
 
The Medi SPICE PRM and PAM is being released in phases and consists of a 
defined set of software processes that contain a comprehensive set of specific 
practices which when utilized assist medical device software development 
organizations to fulfill the regulatory guidelines and standards of the medical 
device industry.  It also addresses the requirements for process assessment 
and can be utilized to facilitate process improvement.  
 
Med-Trace 
 
As traceability is central to the development of regulatory compliant software 
the RSRG decided to develop an assessment method specifically to assist 
companies to adhere to the traceability aspects of the medical device 
software standards. Emanating from the Adept method [33], previously 
developed by the authors, and based upon CMMI
®
 [34] and ISO/IEC 15504-5 
software process reference models, Med-Trace is a lightweight assessment 
method that provides a means of assessing the capability of an organization 
in relation to medical device software traceability.  Med-Trace enables 
software development organizations to gain an appreciation of the 
fundamental traceability best practices based on the software engineering 
traceability literature, software engineering process models (CMMI
®
, ISO/IEC 
15504-5), and the medical device software guidelines and standards. Med-
Trace may be used to diagnose an organization’s weaknesses and strengths 
with relation to their medical device software development traceability 
practices.  
 
Med-Trace is composed of 8 stages. The assessment team typically consists 
of two assessors who conduct the assessment between them.  Stage 1, 
involves a preliminary meeting between the assessment team and the 
company wishing to undertake a Med-Trace assessment. At stage 2, the lead 
assessor presents an overview of the Med-Trace assessment to members of 
the organization who will be involved in subsequent stages. Stage 3, provides 
a brief insight into project documentation.  The first 3 stages are normally 
performed on the company’s premises, but the sample documentation 
collected in stage 3 is sometimes taken off-site as it can then be used to 
assist with the generation of additional questions for stage 4.  
 
During stage 4, the assessment team return onsite and key staff members 
from the organization are interviewed.  A set of scripted questions are utilized 
as a basis for these interviews. These questions are based upon the software 
traceability literature, traceability practices within the CMMI
®
 and ISO/IEC 
15504-5 models, and traceability practices that are required by the medical 
device industry. Additional questions may be asked based on the review of 
the documentation outlined in stage 3. 
 
Stage 5, is a collaborative exercise between the assessors to develop the 
findings report using interview notes.  Stage 6, involves presenting the 
findings report to participating staff in the organization. Stage 7, entails 
collaborating with staff to develop a pathway towards achieving highly 
effective and regulatory compliant traceability practices. The findings report 
provides guidance to the assessed company and focuses on practices that 
provide the greatest benefit in terms of the company’s business goals, in 
addition to their quality and compliance needs.  
 
At Stage 8, the assessed company is revisited approximately 3 months after 
the completion of stage 7 and their progress is reviewed against the 
recommended improvement path. The outcome of this stage is an updated 
improvement path and a final report detailing the progress that has been 
accomplished along with additional recommendations. 
 
Med-Adept 
 
The Adept method [33] was previously developed to provide a lightweight 
assessment of software processes from CMMI
®
 and ISO/IEC 15504-5 and 
was not domain specific. The Adept method was then integrated with 
practices specified in medical device regulatory guidelines and standards to 
produce Med-Adept. Med-Adept [35] is an assessment method that provides 
a means of assessing the software engineering capability for processes in 
relation to medical device software (both application and embedded software). 
 
Med-Adept enables software development organisations to gain an 
appreciation of the fundamental processes from CMMI
®
, ISO/IEC 15504-5 
and IEC 62304 (including additional practices required by other medical 
device guidelines and standards) through diagnosing strengths and 
weaknesses in their software development practices. Med-Adept was 
designed to adhere to 8 of the 10 criteria outlined by Anacleto et al. [36], for 
the development of lightweight assessment methods: low cost, detailed 
description of the assessment process, guidance for process selection, 
detailed definition of the assessment model, support for identification of risks 
and improvement suggestions, conformity with ISO/IEC 15504-5, no specific 
software engineering knowledge required from companies’ representatives, 
and tool support is provided. The two exceptions to the criteria outlined  by 
Anacleto et al. [36] are that no support is provided for high-level process 
modeling and only the authors currently have access to the method. Med-
Adept also inherits the following requirements from Adept: improvement is 
more important than certification, a rating is not required, preparation time 
required by the company is minimised; assessment time is minimized, and 
companies should be enabled to select assessment in  the process areas that 
are most relevant to their business goals. 
 
The main aims of Med-Adept are to either encourage non-medical device 
software development organisations to develop software for the medical 
device industry or to improve the software development processes within 
existing medical device software development organizations. However, the 
Med-Adept method also provides an ideal opportunity to educate software 
development organisations in terms of generic SPI.  Therefore, the 
assessment would still have value even if the assessed software development 
company did not intend becoming a medical device software development 
company in the future. Consequently, Med-Adept provides medical device 
specific and non-medical device specific recommendations.  Assessed 
companies are also supplied with feedback in relation to both CMMI
®
 and 
ISO/IEC 15504-5 which enables such companies to decide whether they wish 
to follow a CMMI
®
 or an ISO/IEC 15504-5 improvement path. Med-Adept 
provides the assessed company with a findings document presented in terms 
of processes from CMMI
®
, ISO/IEC 15504-5 and practices required by 
medical device software standards and regulations (with a particular focus on 
IEC 62304).   
 
Med-Adept is composed of 8 stages which are similar to those in Adept and 
Med-Trace. The assessment team consists of two assessors who conduct the 
assessment between them. Stage 1 involves a preliminary meeting between 
the assessment team and the software company wishing to undergo a 
software process assessment.  The assessment team discuss the main 
drivers for the company embarking upon a Med-Adept assessment and 
establish whether the company is interested in developing software for the 
medical device industry. During stage 2 the lead assessor provides an 
overview of Med-Adept for members of the assessed organisation who will be 
involved in subsequent stages. This session is used to remove any concerns 
that individuals may have. 
 
Stage 3 provides a brief review of project documentation. However, the 
primary source of data for Med-Adept is through a series of process 
interviews conducted during stage 4. In this stage key staff members from the 
assessed organisation are interviewed. There is an interview for each 
process. Each interview is scheduled to last approximately 1.5 hours. To 
enable stage 4 to be completed within 1 day the scope of a single Med-Adept 
assessment is restricted to 4 processes. Each interview involves two 
assessors and at least one representative from the company. Stage 5 is a 
collaborative exercise between the assessors to develop the findings report 
using interview notes for each of the assessed processes. The resultant 
findings report consists of a list of strengths, issues and suggested actions for 
each of the assessed processes.   
Stage 6, involves presenting the findings report to participating staff in the 
organisation. Stage 7, involves collaborating with staff to develop a roadmap.  
This provides guidance to the assessed company presenting practices that 
can provide the greatest benefit in terms of the company’s business goals. 
Companies wishing to develop software for the medical device industry are 
recommended to focus upon establishing working practices that will assist 
them to fulfil the medical device regulations. Stage 8, involves revisiting the 
assessed company approximately 3 to 6 months after the completion of stage 
7 and reviewing progress against the SPI path. The outcome of this stage is 
an updated SPI path and a final report detailing the progress that has been 
accomplished along with additional recommendations. This stage provides 
feedback and assistance to the assessed company after a period of time and 
also assists in compiling research material in terms of SPI experiences.  
 
As Med-Adept is based upon the Adept method, existing Adept questions 
were used as the foundation for the Med-Adept method. Questions were 
added to enable coverage of medical device regulations. Even though each 
assessment component adopts a CMMI
®
 process area name, it also contains 
questions providing coverage of relevant ISO/IEC 15504-5 processes and 
medical device standards and regulations  
 
Of the 12 Adept processes, 11 had medical device regulatory questions 
added for Med-Adept the exception being Measurement and Analysis which 
cannot be mapped against the processes of IEC 62304. Additionally, the 
existing Adept processes (which Med-Adept is founded upon) did not provide 
coverage of 5 IEC 62304 processes (Software Release, Software 
Maintenance, Software Problem Solution, Documentation, Software Safety 
Classification). Therefore, the current version of Med-Adept also does not 
provide coverage of these processes. Additionally, it should also be noted that 
the current release of Med-Adept does not include a Risk Management 
process.  
 
Therefore Med-Adept does not provide complete coverage of all the medical 
device regulations. However, the main aim of Med-Adept is not to provide 
comprehensive coverage of medical device regulations, but rather to assist 
organisations to improve their software practices and to encourage 
organizations to develop medical device software. To encourage the uptake of 
the Med-Adept assessment by software SMEs, on-site interviewing is 
restricted to one day thus minimizing the time and cost associated with the 
assessment. 
 
Medi SPICE-Adept 
The RSRG are currently developing a new assessment method (Medi SPICE-
Adept) that will enable lightweight assessments to be performed against the 
Medi SPICE PAM. Medi SPICE-Adept follows the same structure as Med-
Adept but with several key differences: 
 Different processes then Med-Adept - Due to changes in the configuration 
of the processes that makeup Medi SPICE, Med Adept does not provide 
coverage of all Medi SPICE processes. Medi SPICE-Adept will provide 
coverage of all Medi SPICE processes but currently it consists of only 10 
processes: Configuration Management, Change Request Management, 
Software Requirements Elicitation, Systems Requirements Analysis, 
Software Requirements Analysis, Software Construction, Software 
Integration, Software Testing, Verification, Validation 
 
 Not based on CMMI® – Whereas, Med-Adept was founded upon CMMI® 
questions, ISO/IEC 15504-5  and regulatory processes Medi SPICE-Adept 
is not based upon CMMI
®
 and does not include CMMI
®
 questions. Medi 
SPICE-Adept is instead based upon Medi SPICE processes. 
 
 Includes agile and lean questions - Medi SPICE-Adept, unlike Med-Adept 
contains questions that refer to agile and lean practices. The output from 
an assessment is a set of strengths, issues and recommendations.  As 
companies wish to increase the efficiency of their software development 
practices it was therefore considered essential to include agile and lean 
practices as part of the assessment. 
 
 Reflects changes in latest directives’ and standards - Contains processes 
that are in-line with the latest changes in the MDD and the FDA rules.  
Med-Adept was initially developed to provide assessment of Medi SPICE 
processes that were aligned with ISO 12207:1995, however, both IEC 
62304 and ISO/IEC 15504-5 are now being revised to align with ISO 
12207:2008. It is therefore important that Medi SPICE is also revised to 
align with ISO 12207:2008. Therefore, Medi SPICE-Adept provides 
coverage of the revised Medi SPICE processes. 
 
 May be performed over a number of days. Whereas a Med-Adept 
assessment typically involved only one day of on-site interviews, a Medi 
SPICE-Adept assessment currently consists of 2 days of on-site interviews 
and provides coverage of 10 process areas. However, in the future we plan 
to extend the scope of the assessment to include all 38 Medi SPICE 
processes and 10 subprocesses. Although, it will still be possible for the 
organization to be assessed in as few processes as they wish and in such 
cases the on-site interviews may be completed in one day. 
 
What initial steps may be taken by SMEs  
The first step for a company is to discover if their software comes under the 
umbrella of a medical device as defined by either the revision of the European 
Council’s MDD or the FDA’s MDDS. The second step will then be to become 
aware of what standards need to be adhered to. This can be quite a time-
consuming task for organizations as there are many different standards and it 
is difficult to determine the complete list of appropriate standards and the 
relationship between the different standards.  
The third step is for an organization to benchmark the state of their current 
software development processes against recommended best practices for 
medical device software development. In relation to this the author’s 
recommend adopting a Med-Trace assessment to gain an understanding of 
how the traceability aspects of their software development processes could be 
improved to assist them to achieve regulatory compliance. Additionally, the 
author’s also recommend implementing a Medi SPICE-Adept assessment to 
gain an understanding as to the set of strengths and issues of an 
organization’s current software development processes in relation to 
developing regulatory compliant medical device software. The output from 
implementing both Med-Trace and Medi SPICE-Adept will be a set of 
recommendations that will provide a roadmap to put an organization on the 
correct path towards developing medical device software using compliant 
processes. It should be noted that if an organization decides to implement a 
Medi SPICE-Adept assessment this would remove the need to perform step 2 
as this assessment is based upon Medi SPICE which provides seamless 
alignment across all the required medical device software standards. It will 
then be important for the organization to prioritize the recommendations and 
start to implement them within their organization – this should be performed 
by implementing a few recommendations at a time as opposed to everything 
at once.  
 
After implementing the recommendations over a period of time the 
organization should then embark upon another Medi SPICE-Adept and/or 
Med-Trace assessment to determine the level of improvement in relation to 
their software development processes. The output from this follow-up 
assessment will either be another set of recommendations or an indication 
that adequate processes are now in place for the organization to contact the 
national notified body for an official certification. 
 
 
Conclusion  
The growing requirement for medical device software and the opportunities 
this provides for software SMEs continues to increase.  The necessity for 
regulatory compliance and the lack of clear guidance are often cited as 
barriers to entry to this expanding market. Organizations that are currently 
developing medical device software are mainly focused on achieving 
regulatory compliance rather than also improving their development process 
and increasing their efficiency. For both of these situations the research 
undertaken by the RSRG is of particular value. Medi SPICE is a process 
assessment and improvement model which is domain specific to medical 
device software development.  It has been developed to address the specific 
requirements of medical device software companies.  Med-Trace and Medi 
SPICE-Adept (based on Medi SPICE and Med-Adept) are lightweight 
assessment methods which provide effective mechanisms to assist software 
SMEs to enable them to put processes in place that will enable them to 
perform medical device software development. The RSRG plan to continue to 
build on its extensive experience and knowledge in this area. It is envisaged 
this will include the development of additional assessment methods and tools 
in the future as opportunities for innovation and improvement arise. 
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